The clinical stage at presentation was found to be significantly related to the BC molecular subtype, with 70.7% of Luminal B cases and 60% of HER2 enriched cases presenting at advanced stages, either Stage III or Stage IV (p = 0.002). This evidence concerns the gene ERBB2 and breast cancer.